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Abstract
Patients with chronic respiratory diseases (CRDs) have a disorder in muscle
structure and function, but their function increases with physical progress and
decreases the risk of general, and muscular weakness are more likely to develop
sarcopenia. We randomly selected patients (N = 38) with mean age of 72  1.0
years old men and women elderly with chronic respiratory diseases such as asthma,
COPD, bronchiectasis and obesity with dyspnea score ≥ 2 in MRC index. All
patients after receiving research information and signing informed consent have
gone through performing clinical assessments. They performed femur bone mineral
density (FBMD) and ultrasound on the rectus femoris muscle mid-tight cross-
sectional area (RFMTCSA) in the quadriceps muscle. The significant changes in
BMI were seen in all patients, pre-rehabilitation, BMI = 30  1.06 kg/m2 and post-
rehabilitation, BMI = 29 1.00 kg/m2. In Pearson’s correlation of r = 0.607 between
T-score and Z-score in FBMD and RFMTCSA in pre-rehabilitation, there is a little
bit significant correlation between the variables than in the Pearson’s correlation of
r = 0.910 in post-rehabilitation, P < 0.00. Comparing femur bone and rectus
femoris muscle parameters as indicators for diagnosis of sarcopenia in chronic
respiratory patients, we observed that in rectus femoris muscle, ultrasound is the
most effective foot muscle detector.
Keywords: sarcopenia, femoral bone mineral density, rectus femoris muscle
phenotype, quadriceps muscles, chronic respiratory disease, quality of life
1. Introduction
Chronic respiratory disease (CRDs) is widespread worldwide. It was reported to
be the sixth leading cause of death in the world in 1990 and is now the fourth
leading cause of death and is projected to be the third leading cause of death in the
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world by 2020 [1]. Chronic obstruction of airflow is an important feature of these
patients. CRDs have impaired airway function and lung structures. Some of the
most common chronic obstructive pulmonary diseases, COPD, asthma, occupa-
tional lung disease, pulmonary hypertension and respiratory problems associated
with the patient are due to adverse physical conditions such as for overweight and
obesity. Patients with chronic respiratory illness can suffer from other symptoms
such as frailty, depression, heart attack, fatigue, decreased exercise capacity, and
kidney pain. Exercise is in many cases a strategic way to improve the symptoms of
these diseases. It is now widely reported that proper exercise can be an effective
prevention and treatment strategy for respiratory patients, and this is very impor-
tant in the management of elderly people with chronic respiratory diseases. Recent
studies of extra-pulmonary issues in chronic respiratory patients have shown that
quadriceps muscle is the most important muscle for these patients due to involve-
ment in movement and activities [2, 3]. But accurate and reliable equipment must
be used to evaluate the quadriceps. New scientific studies have used ultrasound
technology as an important and valid device for an accurate evaluation of
quadriceps function and structure.
According to the latest scientific reports [4, 5], the rate of sarcopenia in COPD
patients is about 25%. Severe sarcopenia was 2.5% and only 0.8% obesity associated
with sarcopenia. The incidence of sarcopenia in COPD patients is 15%. It is well
known that respiratory disorders are a very common disease. It is also quite evident
that respiratory distress is a very common disease that affects up to 10% of adults
over 40 years of age and causes high levels of illness and mortality. It is associated
with additional respiratory disorders, such as cardiovascular disease, osteoporosis,
depression, and anemia. Besides, other non-pulmonary complications, such as car-
diovascular disease, bone loss, musculoskeletal disorders, and muscle weakness, can
also adversely affect their health outcomes. Increasing different comorbidities can
damage lung function, decrease quality of life, and increase mortality. In all of these
problems, muscle weakness and osteoporosis is a major problem that needs more
therapeutic intervention. In the general population, osteoporosis risk factors include
female gender, age, low body weight, glucocorticoid intake in chronic patients, and
endocrine problems such as hyperthyroidism and primary hyperparathyroidism.
Recently, reduced skeletal muscle as sarcopenia parameter has been identified as a
risk factor [6]. The major risk factors for osteoporosis in respiratory patients are not
yet clearly understood, but factors such as aging, female gender, low body weight,
and body mass index (BMI) have been associated with reduced BMD in patients
with COPD [6]. But compared to skeletal muscle index, body weight and BMI do
not provide a more accurate reflection of body composition. In one study of aging
and body composition, the prevalence of sarcopenia in the overweight group (BMI
= 25–29) was 8.9% and in the obese group (BMI > 30) 7.1%. Overweight and obesity
are often symptoms of sarcopenia and gradually increase with the prevalence of
chronic respiratory disease. Low body mass index is associated with osteoporosis
risk factors in patients with COPD including low body weight and low BMD [7].
Sarcopenia is a major complication of chronic obstructive pulmonary disease, which
is often seen even without low BMI. However, few studies have been published on
the relationship between sarcopenia and BMD.
1.1 Skeletal muscle dysfunction in CRDs
Musculoskeletal disorders are an important clinical examination that is recog-
nized in chronic respiratory patients. For example, in people with COPD, common
changes in the musculoskeletal system, including quadriceps weakness, atrophy,
and fiber-type shift, each provide independent predictive information of the lung.
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The mechanism that disrupts musculoskeletal function can have negative conse-
quences through the progression of the so-called “healthy age” to sarcopenia and
weakness. Sarcopenia has been described as a decrease in skeletal muscle and a
decrease in physical function dependence, which requires knowledge of current
conditions of the musculoskeletal system to reduce muscle mass and muscle weak-
ness in chronic respiratory patients. Skeletal muscle function is often considered in
common diagnostic criteria, due to muscle weakness and a history of weight loss,
which is often a product of muscle wasting. Both syndromes indicate skeletal
muscle dysfunction, which affects more of these syndromes, the broader effects of
the disease, both inside and outside the lungs, affecting morbidity and mortality in
these patients [8]. Therefore, the presence of sarcopenia may be considered and
provide additional prognostic information provided by skeletal muscle function
markers. Previous studies have reported that a decrease in skeletal muscle mass is
associated with a decrease lung function in patients with COPD. More recently, in
studies of nursing home residents, Carlson et al. [6] showed that peripheral muscle
strength, including hand-grip strength, was associated with maximal stimulating
muscle strength. However, there is a paucity of information on how skeletal
muscle mass changes are associated with pulmonary function in adults without lung
disease.
1.2 Recognizing sarcopenia in CRDs
Some scientific reports suggest that one of the systemic effects of COPD is
sarcopenia. The term is described as an age-related decline in muscle volume and
function. This situation is associated with negative health consequences such as
falling, disability, hospitalization, poor quality of life and mortality. The cause of
sarcopenia is in addition to the consequences of the disease, nutrition, and activities
caused by physiological changes. Sarcopenia can be classified as a physical impair-
ment associated with adverse health consequences. These findings suggest that
sarcopenia is associated with decreased lung function in COPD patients. These
patients also have a relative or absolute increase in fat mass, which can lead to
systemic inflammation, and insulin resistance [9, 14]. In a recent study, body mass
index (BMI) was not significantly associated with lung function, the severity of
dyspnea, quality of life, and decreased skeletal muscle mass.
Skeletal muscle dysfunction is a well-known clinical manifestation in COPD
patients. Key features include quadriceps weakness, atrophy, and type II fiber
alteration, all of which are associated with a poor prognosis independent of lung
function. Sarcopenia describes age-related skeletal muscle loss, leading to an
increased risk of physical disability, poor health, and mortality. Sarcopenia is
increasingly recognized as a clinical syndrome with its contributing factors, includ-
ing physical inactivity, malnutrition, and chronic illness. Since COPD is in some
ways an accelerated disease in the aging process, it is proposed the hypothesis that
sarcopenia is related to COPD patients [10]. In patients with COPD, most studies
addressing skeletal muscle dysfunction have focused on one aspect of sarcopenia,
mainly in the lower limbs. This contradicts international consensus statements on
sarcopenia, which emphasizes the loss of both muscle mass and function in diag-
nostic criteria, and emphasizes the importance of general muscle function. In par-
ticular, evaluation of one aspect of sarcopenia is not sufficient, as the relationship
between muscle mass and strength is nonlinear, and muscle atrophy does not
always lead to dysfunction and there are no functional status weaknesses. The
European Working Group on Sarcopenia in the Elderly (EWGSOP) has developed
practical clinical diagnostic criteria for sarcopenia approved by international orga-
nizations and used to assess the prevalence and impact of this syndrome on disease
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settings and states. Although commonly used in COPD, it is necessary to under-
stand the magnitude and nature of the problem in the disease associated with
atrophy and muscle weakness [11]. Sarcopenia is associated with many common
disease management strategies, including exercise training and nutritional aspects.
Given the emergence of drugs directed to sarcopenia in other disease conditions,
such data may be useful for drug production [12]. In this study, we evaluated the
prevalence and risk factors of sarcopenia in respiratory patients and the effect of
sarcopenia on functional exercise capacity and health status. We also seek to exam-
ine the relationship between sarcopenia and quadriceps strength and to examine
whether exercise training as part of pulmonary rehabilitation can reverse
sarcopenia.
Patients with respiratory disorders have musculoskeletal disorders, but their
function increases with the progression of physical activity and reduces the risk of
general and muscular weakness. Respiratory patients with general and muscular
weakness have higher mortality rates than non-weak patients and are more likely to
have sarcopenia and an increased incidence of the disease. In one study at a British
hospital (2015) [13], the prevalence of sarcopenia was reported to be 14.5% of
COPD patients in British country compared to other European countries. In chronic
respiratory patients, both risk factors (smoking, aging) and their causal mecha-
nisms (endocrine dysfunction and inflammatory cytokines) are common and be
high prevalence. These causes have increased with age and the global prevalence of
recurrent respiratory diseases. Muscle structure and function must be considered
for the diagnosis of sarcopenia. Clinically, the current definition of sarcopenia may
show several defects, especially for quantitative measurement of muscle volume.
Firstly, muscle mass thresholds are defined differently, and this causes patients to
be classified correctly or incorrectly for sarcopenia. The prevalence of sarcopenia in
the elderly also depends on the accepted definition for evaluation. However, the
role of skeletal muscle ultrasound for screening and diagnosis of sarcopenia in the
elderly remains and is important. None of the current definitions of sarcopenia
include it in the diagnostic algorithms currently in the category of specialists.
However, some experts [14–16] believe that using ultrasound in this field is also
useful and this technique is recognizable based on pioneering studies of muscle
mass in healthy individuals and patients with an aging approach. Therefore, most
studies support the use of potentially validated muscle ultrasound to identify
sarcopenia in the elderly. However, since it has been performed in small samples
and a variety of clinical conditions (from healthy subjects to patients with chronic
diseases), no significant recommendations have been made regarding the use of
large-scale muscle ultrasound. In smaller cases, so in the same patients, some mus-
cles may be affected by sarcopenia and other muscles not affected. Innovative
muscle ultrasound studies have been conducted by Abe et al. [19] and his colleagues
have contributed to the development of knowledge of this phenomenon and have
developed specific concepts. They also developed and validated the equations, and
calculated the total body mass index from ultrasound muscle thickness measure-
ments in Japanese and Caucasian subjects, and achieved significant results.
However, the relationship between full-body sarcopenia and specific sarcopenia is
not fully understood and needs further research to identify the indicators. In this
capture, in a small group of healthy adults, the researchers showed that the ratio of
anterior or posterior muscle to ultrasound was not consistent with abdominal lum-
bar mass measured by DEXA. However, according to the researchers’ findings, it
can be concluded that using ultrasound and DEXA to predict sarcopenia indices in
chronic respiratory patients is valid and reliable, but which parameter has the most
impact? It is not clear yet and we need to investigate more in the future. However,
the role of skeletal muscle ultrasound for screening and diagnosis of sarcopenia in
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the elderly is quite clear. But none of the current indicators of sarcopenia include its
diagnostic algorithm. Bonsignore [17] and Marmorato et al. [18] believe that the use
of muscle ultrasound is also potential in this area and is largely based on pioneering
studies in which muscle mass and its architecture are evaluated using this method in
healthy subjects and respiratory patients.
1.3 Sarcopenia indexes in CRDs
1.3.1 Body mass index (BMI)
Body mass index (BMI) should be mounted on a wall using standard hospital
calibration scales, because these parameters are very useful and fruitful in respira-
tory treatment as an indicator of health status. BMI is calculated as body mass (kg)
divided by squared body height (m2). However, this mostly applies to patients with
severe COPD where an increasing BMI is linearly associated with better survival,
while in patients with mild to moderate COPD the lowest mortality risk occurs in
normal to overweight or weight loss in these patients. The World Health Organiza-
tion criteria were used to classify the subjects as low-weight (BMI < 18.5), eutro-
phic (18.5 < BMI ≤ 24.99), overweight (25 ≤ BMI ≤ 29.99) or obese (BMI ≥ 30.00)
[19]. This index and division for respiratory patients can also be cited and so for all
population recognized. The biggest problem with BMI is that when patients with
chronic respiratory disease have a normal weight, they are unable to recognize the
percentage of the muscles of this patient, which is the main cause of her movement
and activity, and in this situation, we need to use more precise equipment the body
composition by BIA (Bioelectrical Impedance Analysis), including the percentage of
muscle, fat, bone, lean mass, hole body mass, is more accurately measured, and this
can be useful in a more accurate diagnosis of sarcopenia in these patients [20].
1.3.2 Skeletal muscle index (SMI)
One of the most important indicators of sarcopenia in chronic respiratory
patients is the skeletal muscle index (SMI), which is measured by factors such as
age, height, weight, ethnicity, gender, and BMI in a valid and reliable formula, and
its rate in an evaluation table according to gender and age is measurable. This index
is the most important factor in the diagnosis of sarcopenia in chronic patients,
especially in patients with respiratory disease. SMI is calculated as a function of
weight and height as follows: (height [m]_0.244_body mass) + (7.8_height) +
(6.6_gender) – (0.098_age) + (ethnicity – 3.3). The SMI index is then calculated by
dividing an individual’s SMI (kg) by his or her height squared (m2). This indicator
can be used as the main factor in the diagnosis of a respiratory patient with
sarcopenia [21].
The gold standard of research for evaluating sarcopenia relies on complete
techniques, cross-sectional imaging, a non-functional, and more structured
approach to routine care. A more practical alternative indicator of lumbar muscle
density in L3 using a normalized computed tomography (CT) is called skeletal
muscle index (SMI). While evidence suggests that decreased lumbar SMI is associ-
ated with adverse clinical outcomes, such as deaths in the lung or colorectal cancers,
little research has investigated how this measure of sarcopenia relates to dyspnea or
decreased exercise tolerance. Although lung cancer patients and respiratory patients
often use chest CT scans as part of their care, fewer respiratory patients receive
lumbar scans. This limits the ability to evaluate sarcopenia using the lumbar SMI
and therefore requires the discovery of the quadriceps SMI instrument as a more
accurate sarcopenia measure. Besides, the measurement of thoracic skeletal muscle,
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which is involved in breathing work, may be associated with better breathing and
better functional capacity [22, 23].
Spencer [24] and Soicher et al. [25] did not report a significant relationship
between SMI and breath intensity. There was also no significant relationship
between SMI, respiratory rate, and 6MWT interval. Similarly, the Cox proportional
hazards model [25] did not show a significant relationship between SMI and manual
weakness. Finally, using this technique, 50 patients with eligible Lumbar Scan
diagnoses were identified and found similar results. Over time, the SMI has gradu-
ally declined unacceptably. There was a significant relationship between Pearson
correlation coefficients in lumbar and thoracic scans in this issue. Their findings
suggest that the definition of SMI-based sarcopenia is not associated with severe
breathing, exercise capacity, or survival in a small sample of patients with advanced
lung cancer. The strengths of the present study include a population with comple-
mentary sarcopenia features, severe breathing and exercise tolerance, and robust
exploratory analysis. Despite the negative results, they demonstrated the feasibility
of measuring sarcopenia using SMI. They were limited by the small sample size and
missing data. Whereas a larger sample provides more power to detect significant
index correlations. They used CT scans performed in the usual stages of care, which
may not meet the exact criteria of future research. Changes in the quality of CT
scans may result in indeterminacy. Besides, it cannot illuminate the severity of
respiratory illnesses and other complications present in diagnostic models to poten-
tially improve the accuracy of treatment models in respiratory patients [26, 27].
1.3.3 Anthropometric indexes
For a more accurate diagnosis of sarcopenia, according to scientific reports,
anthropometry and measurement of body sections such as arms, trunk, pelvis, and
legs are important parameters for measuring anthropometry in the diagnosis of
sarcopenia. A chronic respiratory patient must be normal, since muscle atrophy will
be directly related to muscle weakness and general weakness of the body, and
ultimately lead to a decrease in the physical activity of the patients. In these condi-
tions, the quality of life of the patients is compromised and they are not able to
continue their normal life and eventually the mortality rate increases [28].
1.4 Pulmonary rehabilitation in CRDs
The results of scientific predictions show that pulmonary rehabilitation (PR)
reduces frailty but there is little evidence of this intervention in this area. PR has
been shown to significantly improve patients’ symptoms and quality of life in
patients with respiratory disease. Public daily activities can relieve shortness of
breath and fatigue, as well as increase exercise tolerance, and affect patients’
self-control and feel it. Recently, studies have shown that the lack of association
between fat mass and the 6-minute walk test (6MWT) is one of the general consid-
erations in assessing COPD patient status longitudinally to identify alternatives in
predicting the future of these patients. In addition to improving respiratory and
functional symptoms, pulmonary rehabilitation programs also target elements such
as weakness, depression, inactivity, and fatigue [29, 30].
Jones et al. [31] investigated the interaction of sarcopenia index in patients
with COPD and response to pulmonary rehabilitation. In this study, 622 elderlies
and middle-aged COPD patients were included in the study. An immediate cohort
study was followed over four years of pulmonary rehabilitation in patients with
weakness and COPD. The pulmonary rehabilitation program consisted of an 8-week
outpatient and 2-time weekly and home-based one-time training program.
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The sessions consisted of 1:15 h of training, with 25.6% of participants in the
pulmonary rehabilitation program being a weakness (according to the Freud phe-
notype model), while only 10% of the participants did not meet any of the weakness
criteria. Significant improvements have been reported in a variety of areas includ-
ing the Dyspnea MRC scale, manual dynamometer, chronic fatigue and anxiety,
emotional scores, hospital stress, and depression shuttle score and walking test. All
of these parameters are related to sarcopenia indices in respiratory patients.
Sarcopenia has increased with age and the World Initiative Index for Obstructive
Pulmonary Disease. It can be clearly stated that disorders of the skeletal muscle are
more important in evaluating sarcopenia in chronic respiratory patients [32, 33]. In
the event of any disruption to the structure and function of the large musculoskel-
etal system of the body, especially the lower limbs and the foot, which are the main
cause of movements, there will be widespread changes in weight loss, overweight,
body composition, body diameter, water, fat, muscle percentage. Ultimately, the
amount of physical activity a patient has directly related to their muscles [34, 35].
2. Main objective
The main objective of this study was to evaluate the relationship between rectus
femoris phenotype and femoral bone mineral density as the main indicators of
sarcopenia in chronic respiratory patients following a pulmonary rehabilitation
protocol with a cardiopulmonary exercise test approach (ERS/ATS instructions).
The effect of this relationship on lung function and muscle structure in these
patients has also been investigated.
3. Methodology and materials
3.1 Ethics and Research Committees
This study has been approved by the Ethic Committee and the Research
Committee Parc Sanitari Sant Joan de Deu, in the research group: “Clinical and
epidemiologic research on high-prevalence disorders” (Faculty of Medicine at the
University of Barcelona). All patients who volunteered before signing an informed
consent form had all information about the goals, techniques, possible outcomes,
and therapeutic processes in the pulmonology, rehabilitation, and radio diagnostics
departments. Also, all patient information without personal access is completely
confidential and is for the sole purpose of this research (Figure 1).
3.2 Study design
Figure 2 shows the general design of the study as a work plan of the study.
The patients had asthma, COPD, bronchiectasis and obesity (randomly, 38 men and
women selected from the chronic respiratory community at the hospital) with a
dyspnea score ≥ 2 in MRC index. We evaluated the general characteristics of the
patients including: gender, age, weight, height, BMI and clinical history, spirometry
of lung function, at the pulmonology and rehabilitation departments. Then, they
were referred to the Radio diagnostic department to perform a DEXA scan test to
evaluate the femoral bone mineral density (T-score and Z-score) and ultrasonogra-
phy on the rectus femoris quadriceps muscle (cross-sectional area, distance and
circumference). They performed a 4-month long term a pulmonary rehabilitation
protocol (Table 1), which included: exercise tests—incremental and constant, 12
7
The Main Clinical Indicators of Sarcopenia in Patients with Chronic Respiratory Disease…
DOI: http://dx.doi.org/10.5772/intechopen.91333
weeks, 3 times a week, duration of each session was 1 h 15 min. Breathing tech-
niques, respiratory muscle training and self-management, (ATS-ERS guidelines,
2013–2015) were conducted with the supervision of specialists. Following the pul-
monary rehabilitation protocol, all patients performed assessments as post-
rehabilitation like pre-rehabilitation, according to the protocol study. Main inter-
vention: cardiopulmonary exercise tests (CPET) was developed by American Tho-
racic Society in 2003 [36] as the gold standard with validity and reliability to study a
patient with limited level of exercise and to evaluate improvement of respiratory
patients before and after pulmonary rehabilitation protocol.
3.3 Statistics
Descriptive statistics (frequency, mean values  standard deviation, variance...)
was used to analyze the variables of clinical history and health status indexes in
Figure 1.
Group sessions of chronic respiratory patients in Department of Rehabilitation at Parc Sanitari Sant Joan de Deu.
Figure 2.
Work plan concept (pulmonary rehabilitation protocol).
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preliminary characteristics (age, gender, height, weight, BMI, patients, smoking,
diabetic, hypertension, depression and crisis).
Differences between pre- and post-rehabilitation protocol in assessments of
spirometry, skeletal muscle index (SMI), femur bone mineral density and ultra-
sound rectus femoris muscle in quadriceps, were analysed using t-Student of one
sample T-test, independent sample T-test and paired sample T-test. Evaluation of
correlation between rectus femoris phenotype parameters and femur bone mineral
density indexes was done using Pearson correlation in bivariate method of SPSS.
In this study we received report analyzed from department of electrodiagnostic
on rectus femoris muscle by ultrasound report and femur bone mineral density by
DEXA scan that we used of these figures in assessments of rectus femoris phenotype
and FBMD parameters.
We evaluated all of the variables analysis by SPSS version 21.0 software (SPSS
Inc., 2012, Chicago, IL, USA) and Excel 2016 (office 2016) to be used for database.
Statistical significance was set at P < 0.05.
4. Results
4.1 Measurement preliminary characteristics and clinical history
Table 2 shows that, most of the patients had COPD and the prevalence was
higher in men. We found significant changes in chronic respiratory patient’s BMI
No Exercise Instructions Time
(min)
1 Warm up Walking, rotation of joints in upper limbs and lower limbs, rotation
and stretching of trunk in low back, chest, neck and shoulders and
quadriceps
15
2 Cycling
ergometer or
treadmill
The test began with a 1-min warm-up period at minimal cycle
ergometer load (15 W), with 5- to 10-W increases every 2 min that
were individually selected to maintain the period of load increase in
the 8-to-12-min range. 1-min active recovery using minimal cycle
ergometer load followed the peak load interruption and was followed
by a 6-min passive recovery. Treadmill test is special for patients that
they have knee osteoarthritis and must be attention to standards
indexes in exercise program and initially, the walking speed is very
slow for warm up, but each minute the required walking speed
progressively increases. Total, time for treadmill test 6 min
25
3 Light dumbbell Repetition of light dumbbell (50% resistance) for improvement of
endurance muscle in major muscles, e.g., shoulders, back, low back,
pectoral muscles, trunk sides, quadriceps, leg muscles that more used
in exercise program and influence on breathing
10
4 Respiratory
muscle training
RMT may consist of inspiratory muscle training (IMT) or expiratory
muscle training (EMT) or a combination of both includes: (1)
diaphragmatic reeducation, (2) profound inspiration, (3) inspiratory
hiccups, (4) resistive inspiration with linear pressure load
10
5 Breathing
techniques
(1) Pursed-lips breathing, (2) diaphragmatic (abdominal/belly)
breathing, (3) better breathing tip: stop, reset, continue
5
6 Cold down Light walking, deep breathing, stretching of muscles that more used in
exercise program, e.g., breathing muscle, major muscles, peripheral
muscles that employed during exercise and fresh mind 1 min
10
Table 1.
Cardio-pulmonary exercise protocol (study protocol) in chronic respiratory patients.
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Variables Frequency Valid Present (%) Mean  SEM SD Variance Minimum Maximum Percentile100
Gender Male 22 57
Female 11 28
Missing 5 13
Age (yr) 72  1.0 7.0 54.0 53 88 76.0
Patients COPD Men 18 46
Women 4 10
Asthma Men 1 2
Women 5 13
Bronchiectasis Men 1 2
Women 2 5
Obesity Men 2 5
Women 0 0
BMI—pretest (kg/m2) 30  1.06 6.0 37.0 17 45 33.0%
BMI—posttest (kg/m2) 29  1.00 5.0 33.0 17 40 33.0%
Height (cm) 166  1.0 10.0 108.0 146 196 172.0%
Weight—pretest (kg) 85  3.0 21.00 471.0 45 142 95.0%
Weight—posttest (kg) 84  1.0 21.04 442.0 45 141 94.0%
Recent Hospitalization Yes 16 42
No 17 44
Smoking (yr) 15  3.0 17.00 323.0 00 60 25.0
Capsulate oxygen (h/day) Pre-RHB 33 86 2  0.0 1.0 1.0 1 6 3.0
Post-RHB 33 86 2  0.0 0.0 0.0 0 4 3.0
10 Resp
ira
tory
P
h
ysiology
Variables Frequency Valid Present (%) Mean  SEM SD Variance Minimum Maximum Percentile100
Arthritis Yes 8 50
No 25 36
Cardiovascular disease Yes 12 21.1
No 21 65
Depression Yes 12 31
No 21 55
Diabetic Yes 14 31
No 19 55
Hypertension Yes High 36
No Middle 50
Crisis Pre-RHB High 14 36 Post-RHB High 3 7%
Middle 3 7 Middle 10 26%
Low 10 26 Low 20 52%
Table 2.
Preliminary characteristics and clinical history pre- and post-rehabilitation protocol at the study on P < 0.05.
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from 30  1.06 (kg/m2) before the rehabilitation protocol to 29  1.00 (kg/m2)
after that and we also observed weight loss in all respiratory patients. Regarding the
clinical history of patients, we can see that 42% of patients have a history of
hospitalization and the average rate of smoking in all of them is 15  3.0 years.
A remarkable point in this study, which is very important for respiratory patients,
is the amount of oxygen consumed via O2 capsulate at home which significantly
decreased special in COPD and obesity patients (from 30% to 14%) after the
pulmonary rehabilitation protocol (Figure 3). Table 2 also shows that 50% of the
patients had knee arthritis, 21% cardiovascular disease, 31% depression, 31%
diabetes, and 14% hypertension. Finally, the rate of respiratory crisis with high
intensity decreased significantly (P < 0.05) from 14% to 3% after the pulmonary
rehabilitation. We observed that in all clinical and general health factors, chronic
respiratory patients recovered, presenting improvement in general health and
clinical conditions.
4.2 Measurement of correlation between FBMD and RFMTCSA
In the analysis of Pearson’s correlation r = 0.607 between T-scores and Z-score in
femur bone mineral density (FBMD) and Rectus femoris Mid-Tight Cross Sectional
Area (RFMTCSA) in pre-rehabilitation, there is a significant correlation between
the variables (P < 0.001). In the analysis of the Pearson’s correlation r = 0.910 in
post-rehabilitation between T-score and Z-scores in FBMD and RFMTCSA, there
have a higher significant correlation between variables than pre-rehabilitation on
P < 0.001 (Table 3). It can be said that there is a significant relationship between
FBMD and RFMTCSA after pulmonary rehabilitation protocol, and in both T-score
and Z-score of FBMD with rectus femoris phenotype in RFMTCSA significant
Figure 3.
Oxygen capsulate consumption monitored at home, h/per day, P < 0.05.
Variables One-Sample Test
M df P Lower Upper
Skeletal muscle index pre-RHB 16  32 32 0.001 28.00 36.00
Skeletal muscle index post-RHB 17  34 32 0.001 30.00 38.00
Formula: *Skeletal muscle index (SMI): (height [m] 0.244 body mass) + (7.8 height) + (6.6 sex) – (0.098 age) +
(ethnicity – 3.3).
Table 3.
T-test skeletal muscle index on chronic respiratory airway patients on P < 0.05.
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progress was observed. But in chronic respiratory patients this significant increase
was shown in Z-score higher than T-score. Also we can see that in circumference of
RFMTCSA between pre- and post-rehabilitation protocol did not have significant
change or improvement in correlation with T-score and Z-score (Figure 4).
4.3 Measurement of skeletal muscle index (SMI)
There was a significant increase in musculoskeletal index before (pre-
rehabilitation SMI, mean = 16  32) and (post-rehabilitation SMI, mean = 17  34)
after the pulmonary rehabilitation protocol and they showed positive changes after
the rehabilitation protocol P < 0.001 (Table 3).
4.4 Measurement of spirometry lung function
In the spirometry variables, we can see that most significant changes have
occurred in FEV1/FVC % (mean  SEM = 40.00  7.0 vs mean  SEM = 35.00 
Figure 4.
Correlation between T-score and Z-score of the femur bone mineral density and rectus femoris cross sectional
area in phenotype quadriceps, at P < 0.001.
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7.0) and FEV1/FVC ltr (mean  SEM = 27.00  5.0 vs mean  SEM = 25.00  5.0).
In variable of FEV1 % (mean  SEM = 51.00  2.0 vs mean  SEM = 52.00  2.0),
we saw that there was a significant change in pre- and post-rehabilitation protocol
that cannot be considered as acceptable positive changes but can be seen in the
effectiveness of the pulmonary rehabilitation protocol on spirometry variables in
chronic respiratory patients (P < 0.001) (Table 3). Also, we reported that in
bronchitis patients we have had highest significant in FEV1/FVC % and obesity
patients had more significant in FEV1 %. Asthma patients had increase significant
in FVC perc in pre- and post-rehabilitation protocol (Figure 5).
5. Discussion
In this study, we concluded that by comparing bone, muscles as the main
indicators diagnosis of sarcopenia in chronic respiratory patients, we find that
rectus femoris is the most effective quadriceps muscles in the diagnosis of
sarcopenia. RFMTCSA, Distance, and Circumference muscle parameters, and
DEXA scan at Z-score and T-score of femur bone density after patients’ rehabilita-
tion protocol were significantly different. In other words, in all the ultrasound
indices of the rectus femoris muscle and the DEXA scan data of the femur, we
found positive incremental data. With these considerations in mind, it can be said
that although patients with normal daily activities can control the main indicators of
sarcopenia, they can improve the quality of life and improve the outcomes of all
major muscular and bone markers. Muscle function, lung function, and exercise
capacity require a comprehensive pulmonary rehabilitation program that can help
to prevent muscle weakness and degeneration, as well as reduce important bone
mineral density such as the femur and ultimately their mortality rate. We conclude
that not all factors are necessary to accurately determine the severity of sarcopenia
in patients with chronic respiratory disease, and if specialists consider rectus
femoris ultrasound and femur bone DEXA as the most important factors for
maintaining body stability, they can monitor the latest status of respiratory patients
with sarcopenia and more accurately diagnose the health status and mortality of the
chronic respiratory patients.
We also examined whether spirometry indices are actual measurements and
better predictors of whether CRDs patients develop sarcopenia than the GOLD
Figure 5.
Mean different between spirometry parameters (liter, %) in asthma, bronchiectasis, COPD and obesity patients
in pre- and post-pulmonary rehabilitation protocol.
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staging of the disease. Sarcopenia and obesity have direct effects on lung function
values and we recommend that both elements should be evaluated in all respiratory
patients. We found that respiratory patients with sarcopenia had lower T-score
BMD, which means a higher prevalence of osteoporosis. Also, the presence of
sarcopenia was significantly associated with an increased risk of osteoporosis and
low BMD in both low- and high-weight patient groups. Therefore, in evaluating
patients with CRDs, the presence of sarcopenia should be considered an indepen-
dent risk factor for low BMD.
Lung function is a stronger independent predictor compared to body composi-
tion parameters. Taken together, these parameters are not only useful for assessing
breathing and the treatment process, but are also a potential surrogate for patients’
physical function. Some of the limitations of our study deserve attention. The
relatively small size of our samples, which may be in line with the study hypothesis,
may limit our findings. But our conclusion holds for a whole population, but may
not be entirely true for a population with more prevalent respiratory disease. This
does not mean that the conclusion is highly generalizable. We evaluated body
composition by DEXA, a method widely accepted in scientific research, but not by
the "gold standard" for patients. Besides, we define sarcopenia based on purely
quantitative parameters of body composition, but we are also able to provide infor-
mation on the qualitative dimension of sarcopenia. Finally, the cross-sectional
design of the study allowed for the creation of a causal sequence among the rela-
tionships studied. Body composition may be an important determinant of physical
function in elderly respiratory patients. This research is needed to confirm these
observations on larger samples to improve our understanding of the factors
influencing physical function in a more complex population such as chronic
respiratory patients.
In a study similar to our study, Xiong et al. [13] mentioned the intensity of echo
(EI) was significantly increased by ultrasonography in rectus femoris at all stages of
the GOLD standard following the pulmonary rehabilitation protocol for COPD
patients. However, the cross-sectional area of rectus femoris (RFcsa) in GOLD
standard decreased. This suggests that changes in EI Rectus femoris may occur
earlier in muscle size in patients with COPD. EI was not associated with age, BMI,
and airflow obstruction in our patients. These results show peripheral muscle func-
tion in patients with COPD, whose strength and size of the quadriceps are lower
than in normal subjects. Some researchers have focused on the relationship between
quadriceps strength and thickness with lung function in respiratory patients, which
can be assessed using muscle ultrasound [37]. In another study, the effect of small
and large muscular disorders was examined on admission, especially in quadriceps.
Rongchang [9], reported expected gender differences in quadriceps muscle for
COPD and control groups and similar data were also reported, indicating that in
quantifying quadriceps performance compared to controls, sex and age, mean
QMVC declined 47% and 45% in men and women; a more severe decrease than
previously reported, indicating a significant impairment of quadriceps strength in
COPD patients. In other studies, the effects of small and large muscular disorders,
especially in the quadriceps, was related to the time of hospitalization.
In the study Greening et al. [4] measured the level of quadriceps (Qcsa) as a
marker of muscle mass. This method has previously been confirmed in computed
tomography, Qcsa as well as X-ray absorptiometry in people with COPD and is
useful for patient evaluation in acute conditions and under the need of patient
effort. Regarding the hospital admission, the mean daily proportion of patients with
respiratory distress and disorder was different in the small and large muscle groups.
This indicates that skeletal muscle function is crucial not only for hospital admission
but also for the severity and duration of hospitalization.
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5.1 Response to pulmonary rehabilitation (PR)
As previously mentioned, in patients with chronic respiratory airway disease,
sarcopenia is one of the major problems of these patients, which gradually causes
atrophy and weakness in their muscles, ultimately reducing physical activity and
severely affecting their quality of life. If they do not participate in pulmonary
rehabilitation and physical exercise, they will experience general weakness and a
gradual increase in mortality. Therefore, it can be said that the major part of
sarcopenia is due to musculoskeletal disorders, which include their structure and
physical movement, and should be a top priority in these patients’ pulmonary
rehabilitation programs. In this study, we aimed to investigate sarcopenia factors in
chronic respiratory patients that revealed a significant increase in ultrasound on the
rectus femoris cross-sectional area (RFMTCSA) and rectus femoris peripheral as
well as on DEXA scans on femoral bone mineral density (FBMD) at the Z-score, in
fact, rectus femoris muscle peripheral and femur bone density were among the
factors that had positive effects on factors such as leg muscle strength, quality of
life, lung function and exercise capacity. Regular rehabilitation programs have
shown that they have progressed gradually, but their sarcopenia has dropped
significantly, requiring regular, long-term pulmonary rehabilitation.
6. Conclusions
6.1 Our programme of pulmonary rehabilitation improved
• Parameters of quadriceps muscle specially in COPD patients, RFMTCSA in
pre-rehabilitation = 1.73 and post-rehabilitation = 2.38.
• The rate of femur bone mineral density (FBMD) increased after the pulmonary
rehabilitation protocol.
• We found that there was a significant reduction in BMI and crisis indicators in
respiratory patients, and there was significant difference in the low rate
consumption of oxygen capsule.
• Correlation between RFMTCSA quadriceps and FBMD factors significantly
increased after the pulmonary rehabilitation protocol.
• Significant positive changes were observed in FEV1/FVC its, FEV1/FVC perc,
FVC its, we have had same record scales before and after the pulmonary
rehabilitation protocol.
• Also, patients were also less likely to use capsulate oxygen at home and we
found that home exercises and breathing techniques had a significant impact
on maintaining the effects of the pulmonary rehabilitation protocol and
enhancing self-esteem and confidence in the daily activities of the respiratory
patients, and to the extent that they did so long after the rehabilitation
protocol, exercises, and breathing techniques continued at home.
I hope this research will shed some light on the complications of sarcopenia in
chronic respiratory patients and help to reduce the problems of older patients with
chronic respiratory disease in the near future.
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Abbreviations
ATS American Thorax Society
AT acid lactic threshold
BMI body mass index
BIA bioelectrical impedance analysis
BODE Index body mass index, airflow obstruction, dyspnea and exercise
capacity index
CRDs chronic respiratory disease
COPD chronic obstructive pulmonary disease
DEXA dual-energy X-ray absorptiometry
ERS European Respiratory Society
EI echo intensity
EWGSOP European Working Group on Sarcopenia in the Elderly
EMT expiratory muscle training
FBMD femur bone mineral density
FEV1 forced expiratory volume per 1 second
FVC forced vital capacity
FEV1/FVC expire in the first second of forced expiration (FEV1) to the full,
forced vital capacity (FVC)
GH general health
GOLD global initiative for chronic obstructive lung disease
HRQL health-related quality of life
ILT incremental load test
IMT inspiratory muscle training
kg kilogram
L liter
MRC Medical Research Council
MVV maximal voluntary ventilation
MH mental health
O2 oxygen
PR pulmonary rehabilitation
PSSJD Parc Sanitari Sant Joan de Deu
PF physical functioning
PI value protease inhibitor value
pre-RHB pre-rehabilitation
post-RHB post-rehabilitation
PTH parathyroid hormone
RFMTCSA Rectus Femoris Mid-Tight Cross Sectional Area
RFcsa rectus femoris cross sectional area
RP role physical
RE role-emotional
RMT respiratory muscle training
SMI skeletal muscle index
6MWT 6-minute walking test
SpO2 peripheral capillary oxygen saturation
SF social functioning
SPSS statistical package for the social sciences
SAP intranet PSSJD
US ultrasound
VO2 oxygen uptake
VE ventilation
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VE/VCO2 minute ventilation-to-carbon dioxide output
VD/VT dead space over tidal volume
VC vital capacity
VT vitality
WT walking test
WHO World Health Organization
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